Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

In the second approval, the FDA has lifted the restriction to post-menopausal on use of Verzenio in advanced breast cancer, making it an option for all adults, including pre- and peri-menopausal ...

Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

Genentech, part of the Roche Group ( OTCQX:RHHBY) ( OTCQX:RHHBF) ( OTCPK:RHHVF ), announced that the U.S. FDA has rejected ...

The goal with ProKidney's rilparencel-branded therapy is “to demonstrate the therapy’s potential to preserve kidney function ...

A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

Sales of Kisqali, which treats metastatic breast cancer, surged 64% globally on a constant currency basis in the three months to June, the company said in its second-quarter sales report. That ...

Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

Last year, Kisqali brought in $1.2 billion for Novartis from its already-approved uses as first- or second-line therapy for advanced and metastatic HR+, HER2- breast cancer, another setting that ...

In a final draft guidance, the committee recommended the treatment for HR-positive HER2-negative early breast cancer patients, regardless of lymph node involvement.